Anna I Guerdjikova1,2,3, Stephanie Williams1,2,3, Thomas J Blom1,2,3, Nicole Mori1,2,3, Susan L McElroy1,2,3. 1. Drs. Guerdjikova and McElroy and Ms. Mori are with the Lindner Center of HOPE in Mason, Ohio, and the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine in Cincinnati, Ohio. 2. Mr. Blom is with the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati College of Medicine in Cincinnati, Ohio. 3. Ms. Williams is with the Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio.
Abstract
Objective: The goal of this study was to obtain preliminary data on the usefulness of the combination of phentermine and topiramate extended release (phentermine-topiramate) in binge-eating disorder (BED) associated with obesity or overweight. Design: Ten participants with BED and obesity or overweightness with at least one weight-related complication received phentermine-topiramate in an open-label, prospective, 12-week trial. The primary outcome measure was change in weight. The study was registered under the identifier NCT02659475 at ClinicalTrials.gov. Results: Seven participants completed the study. Phentermine-topiramate treatment was associated with significant reductions in weight, body mass index, binge-eating episode frequency, and measures of global clinical severity, eating disorder psychopathology, and obsessive-compulsive symptoms. Mean daily dose of phentermine-topiramate at endpoint was 6.8 to 41.4mg per day. The most common adverse event (AE) was dysgeusia. There were no serious AEs, and no participants displayed symptoms of medication misuse or withdrawal. Conclusion: Phentermine-topiramate could be helpful for weight loss and reduction of binge-eating symptoms in patients with obesity or overweight in addition to BED. Controlled studies are warranted.
Objective: The goal of this study was to obtain preliminary data on the usefulness of the combination of phentermine and topiramate extended release (phentermine-topiramate) in binge-eating disorder (BED) associated with obesity or overweight. Design: Ten participants with BED and obesity or overweightness with at least one weight-related complication received phentermine-topiramate in an open-label, prospective, 12-week trial. The primary outcome measure was change in weight. The study was registered under the identifier NCT02659475 at ClinicalTrials.gov. Results: Seven participants completed the study. Phentermine-topiramate treatment was associated with significant reductions in weight, body mass index, binge-eating episode frequency, and measures of global clinical severity, eating disorder psychopathology, and obsessive-compulsive symptoms. Mean daily dose of phentermine-topiramate at endpoint was 6.8 to 41.4mg per day. The most common adverse event (AE) was dysgeusia. There were no serious AEs, and no participants displayed symptoms of medication misuse or withdrawal. Conclusion:Phentermine-topiramate could be helpful for weight loss and reduction of binge-eating symptoms in patients with obesity or overweight in addition to BED. Controlled studies are warranted.
Entities:
Keywords:
Qsymia®; binge eating; obesity; phentermine-topiramate; weight loss
Authors: Susan L McElroy; James I Hudson; Julie A Capece; Karen Beyers; Alan C Fisher; Norman R Rosenthal Journal: Biol Psychiatry Date: 2007-01-29 Impact factor: 13.382
Authors: Ronald C Kessler; Patricia A Berglund; Wai Tat Chiu; Anne C Deitz; James I Hudson; Victoria Shahly; Sergio Aguilar-Gaxiola; Jordi Alonso; Matthias C Angermeyer; Corina Benjet; Ronny Bruffaerts; Giovanni de Girolamo; Ron de Graaf; Josep Maria Haro; Viviane Kovess-Masfety; Siobhan O'Neill; Jose Posada-Villa; Carmen Sasu; Kate Scott; Maria Carmen Viana; Miguel Xavier Journal: Biol Psychiatry Date: 2013-01-03 Impact factor: 13.382
Authors: Susan L McElroy; Anna I Guerdjikova; Erin L Winstanley; Anne M O'Melia; Nicole Mori; Paul E Keck; James I Hudson Journal: Int J Eat Disord Date: 2011-04 Impact factor: 4.861
Authors: Susan L McElroy; Lesley M Arnold; Nathan A Shapira; Paul E Keck; Norman R Rosenthal; M Rezaul Karim; Marc Kamin; James I Hudson Journal: Am J Psychiatry Date: 2003-02 Impact factor: 18.112
Authors: Nasreen Alfaris; Alyssa M Minnick; Christina M Hopkins; Robert I Berkowitz; Thomas A Wadden Journal: Expert Opin Pharmacother Date: 2015-06 Impact factor: 3.889